Neurogene Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Neurogene Inc.
Former names: Neoleukin Therapeutics, Inc. Aquinox Pharmaceuticals, Inc Aquinox Pharmaceuticals (USA) Inc
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Headquarters city: New York
Headquarters state / province: New York
Headquarters country: Canada
Fiscal year end: December
Ticker symbol: NGNE
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001404644
EIN: 98-0542593

Board of directors

Follow this board

Christine Mikail Cvijic · Director · President and CFO
Since 2026
Cory S. Freedland · Director
Since 2023
Erin Lavelle · Director
Since 2023
Felix Baker · Director Overboarded
Since 2023
Julian Baker · Director Overboarded
Since 2023
Keith Woods · Director
Since 2023
Martin Babler · Director
Since 2023
Rachel McMinn · Director · Chief Executive Officer
Since 2023
Robert Baffi · Director
Since 2023
Robert Keith Woods · Director
Since 2023
Rohan Palekar · Director
Since 2023
Sarah B. Noonberg · Director
Since 2023
Todd E. Simpson · Director
Since 2023

Chief executives

Rachel McMinn · Chief Executive Officer

Since December 2023

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Robert Baffi

94.6%
Rohan Palekar

99.7%

Board connections

7 of this board's directors also sit on 23 other boards.

Shared director Other board Same sector +7 more in the list below

Prelude Therapeutics Incorporated
via Felix Baker, Julian Baker and Martin Babler
TScan Therapeutics Inc.
via Felix Baker, Julian Baker and Keith Woods
ACADIA Pharmaceuticals Inc.
via Felix Baker and Julian Baker
BeOne Medicines Ltd.
via Felix Baker and Julian Baker
Bicycle Therapeutics plc
via Felix Baker and Julian Baker
DBV Technologies S.A.
via Felix Baker and Julian Baker
Denali Therapeutics Inc.
via Felix Baker and Julian Baker
Immunocore Holdings plc
via Felix Baker and Julian Baker
Incyte Corp.
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc
via Felix Baker and Julian Baker
Kodiak Sciences Inc
via Felix Baker and Julian Baker
Kymera Therapeutics Inc.
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc.
via Felix Baker and Julian Baker
Replimune Group Inc.
via Felix Baker and Julian Baker
vTv Therapeutics Inc.
via Felix Baker and Julian Baker
Alumis Inc.
via Martin Babler
Avalyn Pharma Inc.
via Erin Lavelle
Jade Biosciences Inc.
via Erin Lavelle
MapLight Therapeutics Inc.
via Martin Babler
Protagonist Therapeutics Inc.
via Sarah B. Noonberg
Rocket Pharmaceuticals Inc.
via Keith Woods
X4 Pharmaceuticals Inc.
via Keith Woods
Xencor Inc.
via Todd E. Simpson

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $1,133,569; 17 sales by 4 insiders

Date	Insider	Transaction	Shares	Price	Value
Jul 7, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−4,200	$36.13	$151,763
Jul 6, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−600	$36.02	$21,613
Jul 2, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−2,531	$34.58	$87,519
Jul 2, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−1,530	$35.23	$53,897
Jul 1, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−739	$34.06	$25,170
May 6, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−4,800	$30.07	$144,336
May 6, 2026	Christine Mikail Cvijic Director, Officer (President and CFO)	Open-market sale	−4,800	$32.44	$155,712
Mar 26, 2026	Cvijic Christine Mikail Officer (President and CFO)	Open-market sale	−2,558	$21.62	$55,304
Mar 26, 2026	Rachel McMinn Director, Officer (Chief Executive Officer)	Open-market sale	−3,352	$22.07	$73,979
Mar 26, 2026	Jordan Julie Officer (Chief Medical Officer)	Open-market sale	−828	$21.89	$18,125
Mar 13, 2026	Cobb Stuart Officer (Chief Scientific Officer)	Open-market sale	−3,991	$20.41	$81,456
Mar 13, 2026	Cvijic Christine Mikail Officer (President and CFO)	Open-market sale	−2,387	$20.42	$48,743
Mar 13, 2026	Cobb Stuart Officer (Chief Scientific Officer)	Open-market sale	−2,658	$21.34	$56,722
Mar 13, 2026	Cvijic Christine Mikail Officer (President and CFO)	Open-market sale	−1,395	$21.25	$29,644
Mar 13, 2026	Cobb Stuart Officer (Chief Scientific Officer)	Open-market sale	−148	$22.08	$3,268

Reviews (0)

No reviews yet. Be the first to write one.